MYC and hereditary clear cell renal cell carcinoma: It has been shown that both PPARα pharmacological antagonism and siRNA‐mediated PPARα KD reduce the expression of c‐Myc, cyclin D1 and CDK4 in renal cell carcinoma (RCC) in vitro models 53.